Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.34 |
| ▸ | F2 | P00734 | 3/20 | 0.33 |
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | KHK | P50053 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14978753 | 0.92 | TP53 (0.42) | TP53GPR119PER2KHK | |
| Trifluoroacetic Acid SCHEMBL14966698 | 0.88 | GPR119 (0.43) | TP53DPP4DPP7KCNH2GPR119 | |
| SCHEMBL14978022 | 0.87 | TP53 (0.38) | TP53GPR119PER2KHK | |
| SCHEMBL14978691 | 0.83 | TP53 (0.37) | TP53GPR119PER2 | |
| Trifluoroacetic Acid SCHEMBL14966444 | 0.83 | TP53 (0.36) | TP53DPP4KCNH2GPR119F2 | |
| SCHEMBL16163458 | 0.80 | TP53 (0.51) | TP53GPR119 | |
| SCHEMBL16169604 | 0.79 | TP53 (0.51) | TP53PER2KHK | |
| SCHEMBL16172053 | 0.79 | TP53 (0.42) | TP53KCNH2GPR119PER2KHK | |
| SCHEMBL14970201 | 0.76 | GPR119 (0.49) | TP53GPR119 | |
| SCHEMBL3604029 | 0.74 | TP53 (0.58) | TP53KCNH2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | GPR119, UTS2R, GPR139 | TP53 4454/4885DPP4 1179/4885DPP7 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.